SETH LERNER to Clinical Trials as Topic
This is a "connection" page, showing publications SETH LERNER has written about Clinical Trials as Topic.
Connection Strength
0.970
-
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. J Clin Oncol. 2022 05 01; 40(13):1500-1505.
Score: 0.141
-
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46.
Score: 0.137
-
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
Score: 0.121
-
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15.
Score: 0.085
-
Reply by the authors. Urology. 2014 Aug; 84(2):495-6.
Score: 0.084
-
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014 Feb; 83(2):262-4.
Score: 0.080
-
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
Score: 0.076
-
BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42.
Score: 0.062
-
Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53.
Score: 0.056
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
Score: 0.040
-
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
Score: 0.035
-
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):703-6.
Score: 0.023
-
Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
Score: 0.013
-
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol. 2001 Oct; 166(4):1316-21.
Score: 0.009
-
Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol. 1998 Sep; 10(5):479-84.
Score: 0.007